FOIL starts NYSE trading at $22; VOGX also debuts, no retail IPO window verified (2026)

Wednesday, August 12 is a normal NYSE and Nasdaq trading day. The practical takeaway: FOIL has moved from price discovery to its expected first trading session, while VOGX is also debuting—but neither has a verified mainstream-broker IPO allocation window. 1

Today's spotlight: Londian Wason New Energy Tech (FOIL)

Status: Priced at $22 per ADS, the top of its prior $20-$22 range; NYSE trading is expected to begin today. The offering is expected to close Thursday, August 13, subject to customary conditions. 2

Business in one sentence: Londian Wason makes electrolytic copper foil used in lithium-ion batteries and electronic-circuit applications. 3

Why retail investors care: This is a direct bet on a battery-supply-chain manufacturer rather than a broad clean-energy theme. The company says it supplied about 111,985 metric tons of lithium-ion battery copper foil in 2025 and held a 7.6% global share by sales volume, based on Frost & Sullivan data cited in its IPO materials. Its named customers include CATL, BYD, LG Energy Solution, Samsung SDI and Panasonic. 4

The number to watch: The deal grew from roughly 3.6 million ADSs in the initial calendar terms to about 4.3 million ADSs, producing approximately $94.3 million in gross proceeds and about $87 million in expected net proceeds. The company says it plans to use the money for production expansion, facility upgrades, research and development, manufacturing efficiency and product expansion. 2

Risk to monitor: FOIL is exposed to battery demand, copper-foil pricing and execution on capacity expansion. The IPO also creates dilution: the offered ADSs are newly issued, and underwriters have a 30-day option for up to 642,857 more ADSs. 2

Minimum buy-in and broker access: $22 is the IPO price, not a verified retail minimum. No public allocation notice through Robinhood, Fidelity, Schwab, E*TRADE or Webull was verified. If FOIL appears in a brokerage app today, that is ordinary secondary-market trading—not proof that the $22 IPO was available to that account.

Actionable now

No US IPO allocation met all four checks for this edition: public offer terms, a live deadline, a minimum buy-in and a verified mainstream-broker path. VOGX has priced, but its public release names the underwriter and expected closing date—not a retail order channel. 5 6

Ticker	Price range	Minimum buy-in	Deadline	Verified brokers	Status
None verified	—	Not disclosed	No public allocation window found	None publicly verified	Watch only

Market pulse

VOGX priced at the top of its range. Vogenx sold 6.25 million shares at $13, expects about $81.3 million in gross proceeds and is expected to start Nasdaq trading today. It is a clinical-stage biotech, so the value still depends on development and regulatory milestones rather than current product sales. 5
Selective biotech demand is still showing up. BioSpace reported that BlossomHill increased its offering to nearly 9.4 million shares and expects $150 million, versus an initial target of about $129.1 million. Latigo raised about $345.6 million, above its earlier $285.2 million target. Those are deal-size and demand signals for selected issuers, not proof that every new listing will trade higher. 7
Defense technology remains a live IPO theme. Lyntris is marketing 24 million shares at $19-$22, with a reported backlog of $923.9 million as of June 30. Reuters also reported a six-month net loss of $13 million on $241 million of revenue. The combination is simple to read: a large backlog, but a company that is not yet profitable. 8

HK desk

No Hong Kong public subscription is verified as open today or closing by Friday, August 14. The accessible ET Net IPO route returned an unavailable-page response, while HKEX's public page available in the current search is a newly listed-securities page, not a live subscription table. That leaves this desk at no verified action, rather than turning a listing notice or an old offer into a current application opportunity. 9

On the radar: August 12-26

Deal	Pricing date	Expected listing	Terms	Why watch
Lyntris (LYNX)	Not disclosed	Aug. 19, NYSE	24M shares at $19-$22; about $492M at the midpoint	Defense sensors and software, a large backlog, and an acquisition-led growth story; the reported loss makes execution and profitability the check. 6 8

The reviewed public calendars did not disclose a separate LYNX pricing date or another dated traditional US company IPO with complete terms inside the next two weeks. The radar stays short rather than padding it with undated filings, funds or warrant events.

Market information only, not investment advice. IPO terms, dates and access can change before a final prospectus, pricing or listing.